Sublimaze 2/10 Ml 2ml/10 ml Injection
PDF Leaflet Revision Date: 24 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Opioid analgesic supplement during anaesthesia.
Dosage (summary)
1-10 u03bcg/kg for induction; 0.5-10 u03bcg/kg for bolus; 0.5-5 u03bcg/kg/h for infusion.
Onset of Action / Duration
Onset: 1 min, Duration: ~30 mins
Special Populations
- Elderly
- Debilitated patients
- Renal impairment
- Obese patients
- Children (2-12 years)
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding; may cause neonatal withdrawal syndrome.
Key Drug Interactions
- CNS depressants
- MAO inhibitors
- CYP3A4 inhibitors
- Serotonergic agents
Contraindications
- Known intolerance to fentanyl
- Uncontrolled bronchial asthma
- Severe respiratory depression
- Comatose patients
- Concurrent MAO inhibitor use
Common side effects
- Nausea
- Vomiting
- Bradycardia
- Hypotension
- Muscle rigidity
Counselling Points
- Avoid driving for 24 hours post-administration.
- Monitor for signs of respiratory depression.
- Keep medication secure to prevent misuse.
Serious warnings
- Risk of respiratory depression
- Potential for opioid dependence
- Tolerance may develop
- Serotonin syndrome risk
Important Disclaimer
The Sublimaze 2/10 Ml 2ml/10 ml Injection professional information leaflet below is the property of Piramal Critical Care South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
